Examiner: BUCCINI, MICHELLE CALLAHAN

Tech Center 1600 • Art Units: 1643 1654 1675 1682

This examiner grants 0% of resolved cases

Performance Statistics

—

Allow Rate

-60.0% vs TC avg

Total Applications

—

Interview Lift

Avg Prosecution Days

Based on 0 resolved cases, 2023–2026

2.6%

§101 Eligibility

16.9%

§102 Novelty

27.3%

§103 Obviousness

24.7%

§112 Clarity

App #	Title	Status	Assignee
18240201	DIAGNOSIS AND TREATMENT OF PRIMARY GRAFT DYSFUNCTION FOLLOWING LUNG TRANSPLANT	Final Rejection	Northwestern University
18554340	NOVEL THERAPIES WITH ENGINEERED EFFECTOR CELLS	Non-Final OA	THE SCRIPPS RESEARCH INSTITUTE
18580302	ALPHA-HEMOLYSIN VARIANTS FORMING NARROW CHANNEL PORES AND USES THEREOF	Non-Final OA	Roche Sequencing Solutions, Inc.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.